-
Mashup Score: 1Isa-Kd Prolongs PFS to Almost Three Years in Early Relapsed MM Follow-up Study | ASH Clinical News | American Society of Hematology - 2 year(s) ago
Katie Robinson is a medical writer based in New York. In patients with early relapsed multiple myeloma (MM), the addition of the anti-CD38 antibody isatuximab (Isa) to carfilzomib-dexamethasone (Kd) maintained the improved progression-free survival (PFS) reported in interim results of the phase III IKEMA study, according to a longer-term analysis of the study published in Blood Cancer Journal. 1 “Isa-Kd is a very active regimen in patients with early relapsed MM, reporting a PFS of close to three years,
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
A study of isatuximab and cemiplimab in 3 lymphoma subtypes will not continue, for reasons unrelated to safety.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Isatuximab + #cemiplimab had manageable safety & modest efficacy in patients with R/R classic Hodgkin #lymphoma. However, the study was terminated due to the limited efficacy and lack of synergy of the combination. https://t.co/1FPhbIYGT1
-
-
Mashup Score: 0
Enrique Ocio, MD, PhD, Hematology Department head, Marqués de Valdecilla University Hospital, Santander, Spain, discussed the convenience seen in subcutaneous isatuximab.
Source: AJMCCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
ASCO Spotlight With Enrique Ocio, MD, PhD: Advantages of Sub-Q #Isatuximab for RRMM https://t.co/TM3248Cpeb
-
-
Mashup Score: 3
Addition of isatuximab plus pomalidomide–dexamethasone resulted in a 6·9-month difference in median overall survival compared with pomalidomide–dexamethasone and is a new standard of care for lenalidomide-refractory and proteasome inhibitor-refractory or relapsed multiple myeloma. Final overall survival analysis follow-up is ongoing.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
ICYMI: follow-up analysis of ICARIA-MM – #Isatuximab plus #pomalidomide and low-dose #dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple #myeloma https://t.co/x6UqhnnhEK #mmsm
-
-
Mashup Score: 2
Addition of isatuximab plus pomalidomide–dexamethasone resulted in a 6·9-month difference in median overall survival compared with pomalidomide–dexamethasone and is a new standard of care for lenalidomide-refractory and proteasome inhibitor-refractory or relapsed multiple myeloma. Final overall survival analysis follow-up is ongoing.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Online first: follow-up analysis of ICARIA-MM – #isatuximab plus #pomalidomide and low-dose #dexamethasone vs pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple #myeloma https://t.co/x6UqhnESwi #mmsm
-
-
Mashup Score: 2
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.
Source: The OncologistCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
EMA Review of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma #MultipleMyeloma #Isatuximab #Pomalidomide #Dexamethasone https://t.co/TGzYtWQl61 https://t.co/jiwIzMXeQI
-
-
Mashup Score: 0
Thomas Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses interim analysis results from the Phase…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#IKEMA: #Isatuximab addition to Kd improves depth of response in #Myeloma, w/ Thomas Martin from @UCSFMedicine: https://t.co/IdeC0OfyZt #EMN #EMN21 #HemOnc #MultipleMyeloma #MMSM #MyelomaACTIONmonth #IAMRESILIENT2021 #ImmunoOnc #CTSM #TrialUpdate
-
-
Mashup Score: 2
Isatuximab in combination with carfilzomib and dexamethasone recommended for approval in relapsed multiple myeloma after Phase III IKEMA trial
Source: Oncology CentralCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Isatuximab has been recommended for approval in combination with carfilzomib and dexamethasone in relapsed #multiplemyeloma! Catch up with the latest news on @OncologyCentral https://t.co/suz2t2yfBC
-
-
Mashup Score: 3
Isatuximab in combination with carfilzomib and dexamethasone recommended for approval in relapsed multiple myeloma after Phase III IKEMA trial
Source: Oncology CentralCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Isatuximab has been recommended for approval in combination with #carfilzomib and #dexamethasone in relapsed #multiplemyeloma. Read the latest news now: https://t.co/UALPV6sKFn
-
-
Mashup Score: 0IKEMA subgroup analysis: Isa + Kd in patients who previously underwent transplantation - 4 year(s) ago
Thomas Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses the results of a subgroup analysis…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Phase III IKEMA subgroup analysis: #Isatuximab + Kd in patients with relapsed #Myeloma with prior transplantation, w/ @TomBmt133 of @UCSFCancer: https://t.co/KML3BTvORD #TCTM21 @ASTCT #HemOnc #MultipleMyeloma #MMSM #ImmunoOnc #CTSM #TrialUpdate
-
In patients with early relapsed #multiplemyeloma #MM, the addition of the anti-CD38 antibody #isatuximab to #carfilzomibdexamethasone was found to maintain the improved PFS that was reported in interim results of the phase III IKEMA study https://t.co/sk622HhCOC